Rye Forseth's questions to Soleno Therapeutics Inc (SLNO) leadership • Q2 2025
Question
Rye Forseth asked about any emerging challenges or 'pain points' in the patient start form process that could be addressed in the coming quarters. He also inquired about how early patient compliance trends are tracking since the launch.
Answer
CEO Anish Bhatnagar explained that with a very strong start of 646 patient forms, it is difficult to predict specific pain points for this first-ever hyperphagia drug launch, but the company is monitoring variables like seasonality. Regarding compliance, he stated that while it is too early for detailed data, observed discontinuation rates are substantially lower than those seen in clinical trials, which already had high compliance.